Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including pivotal-stage product candidates against a range of targets. Our mission is to become the world leader in developing better and safer antibody-based oncology products addressing clear unmet pediatric and adult medical needs. With the right partnerships and collaborations, we envision changing the course of cancer care and its outcomes.
Looking for a particular Y-mAbs Therapeutics, Inc. employee's phone or email?
Y-mAbs Therapeutics, Inc. Questions
The Y-mAbs Therapeutics, Inc. annual revenue was $84.6 million in 2026.
Courtney Dugan is the Vice President, Head of Investor Relations and Corporate Affairs of Y-mAbs Therapeutics, Inc..
104 people are employed at Y-mAbs Therapeutics, Inc..
Y-mAbs Therapeutics, Inc. is based in New York, New York.
The NAICS codes for Y-mAbs Therapeutics, Inc. are [5413, 54, 325, 541, 32, 54138].
The SIC codes for Y-mAbs Therapeutics, Inc. are [28, 283].
Top Y-mAbs Therapeutics, Inc. Employees
-
Doug Gentilcore
Founder at Y-mAbs Therapeutics, Inc.
Severna Park, MD, US25+ -
Sue Smith
SVP, CCO at Y-mAbs Therapeutics, Inc.
New York, NY, US35+
Related Companies
